FAP and neoplasm: Compared to either NT‐T cells or no treatment, intravenous administration of a low dose (1 × 106) of FAP‐CAR‐T cells significantly reduced tumor growth (adjusted P < 0.0001 by Type II ANOVA for both control comparisons; Figure 6d), and significantly increased survival time of treated mice (both P < 0.0001 by the Log‐Rank test; Figure 6e).